InvestSMART

Argent Biopharma Limited (ASX:RGT)

ALERT: Price-sensitive ASX Announcement for RGT
Current share price for RGT : $0.055 0.02 (57.14%)+
Announcement
Release
7 Jul 2026 9:23AM
Price at Release
$0.035
Full Release
download
Summary
Argent BioPharma Ltd has executed a significant global licensing agreement with Splash Beverage Group Inc for their epilepsy treatment, CannEpil®. The deal provides Argent with a US$5.5 million upfront benefit through the forgiveness of convertible debt to Mercer, enhancing their financial position by removing secured liabilities. Argent maintains ownership of the CannEpil® intellectual property and manufacturing rights while agreeing to a 15% royalty on net revenues from future sales. This agreement, aimed at the US market, prioritizes regulatory approvals and strengthens Argent's strategic focus and balance sheet.
Key Points
  • Argent BioPharma Ltd has entered into a global licensing transaction with Splash Beverage Group Inc for CannEpil®.
  • The transaction includes an upfront consideration of US$5.5 million structured through the forgiveness of equivalent convertible debt owed to Mercer Street Global Opportunity Fund.
  • Argent retains ownership of CannEpil® intellectual property and manufacturing rights.
  • Argent will receive a 15% royalty on net revenues from future CannEpil® sales by Splash Beverage Group.
  • The transaction strengthens Argent’s balance sheet by eliminating significant secured debt.
  • Splash Beverage Group is tasked with regulatory approvals, including filing an NDA with the FDA following successful clinical trials.
  • CannEpil® is a treatment for drug-resistant epilepsy and has established access pathways in several countries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.